ZEVASKYN commercial ramp is progressing with 3 patients treated in Q1 and 6+ biopsies expected in Q2, but the company remains pre-profitability with widening losses. The $168.3M cash runway provides ~2 years of funding at current burn rates. The ABO-701 licensing adds pipeline optionality but is early-stage (IND filing H2 2027). Monitor Q2 patient treatment cadence and any guidance on revenue trajectory.
ABEO drugs
ABEO drug pipeline →Price Chart
Executive Summary
Abeona Therapeutics reported Q1 2026 net product revenue of $8.7M, up from $2.4M in Q4 2025, driven by three ZEVASKYN patient treatments. Net loss widened to -$17.1M (-$0.30/share) from -$12.0M (-$0.24/share) in Q1 2025, reflecting increased SG&A costs from commercial scaling and a $7.0M upfront licensing payment for the new ABO-701 T-cell therapy program. Cash and investments totaled $168.3M, down from $191.4M at year-end 2025.
Key Financial Metrics
Key Facts
- Q1 2026 net product revenue of $8.7M vs $2.4M in Q4 2025 (quarter-over-quarter increase of $6.3M)
- Three ZEVASKYN patient treatments completed in Q1 2026; one additional in early Q2
- QTC network expanded to six sites with activation of NY-Presbyterian/Columbia and CHOP
- Net loss of -$17.1M (-$0.30/share) vs -$12.0M (-$0.24/share) in Q1 2025
- Cash, cash equivalents and short-term investments of $168.3M as of March 31, 2026
- In-licensed ABO-701 (PSMA-SIR-T) engineered T-cell therapy for prostate cancer; $7.0M upfront payment
- Ophthalmology programs deprioritized as part of portfolio optimization
- Published coverage policies in place for 95% of commercially insured U.S. lives
Financial Impact
Q1 2026 net product revenue $8.7M; net loss -$17.1M; cash burn ~$23.1M in Q1
Risk Factors
- Commercial execution risk, ZEVASKYN revenue still nascent with only 3 patients treated in Q1
- Widening net loss and operating expenses as commercial infrastructure scales
- ABO-701 is pre-clinical; IND filing not expected until H2 2027 with no near-term value
- Cash burn of ~$23M/quarter; runway of ~7 quarters at current pace
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-022610 |
| Document: form8-k.htm | 0001493152-26-022610 |
| Document: 0001493152-26-022610-index-headers.html | 0001493152-26-022610 |
| Document: 0001493152-26-022610-index.html | 0001493152-26-022610 |
| Document: 0001493152-26-022610.txt | 0001493152-26-022610 |
| 8-K Data (Synthetic) | 0001493152-26-022610 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $2.59 Now $2.60 +0.39% settles Nov 18
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers